Aardvark Therapeutics, Inc. 8-K

What Happened Aardvark Therapeutics, Inc. filed a Current Report on Form 8-K on May 14, 2026 (Item 8.01) announcing that the U.S. Food and Drug Administration has placed a full clinical hold on the company’s investigational new drug (IND) application for ARD-101. The company attached a press release announcing the action as Exhibit 99.1 to the filing. The Form 8-K was signed by CEO Tien-Li Lee, M.D.

Key Details

• Event: FDA placed a full clinical hold on the IND for ARD-101.
• Filing date: Form 8-K and press release dated May 14, 2026 (Exhibit 99.1).
• Company: Aardvark Therapeutics, Inc. (ticker: AARD); CEO signing the filing: Tien-Li Lee, M.D.
• The Form 8-K does not disclose the reason for the hold or any planned next steps.

Why It Matters A full clinical hold is a regulatory action that directly affects a drug candidate’s clinical development under the IND named in the filing. Investors should note that Aardvark has reported the hold but has not provided details or a timeline for resolution in this filing. Key near-term items for investors to watch are any follow-up communications from Aardvark or the FDA explaining the basis for the hold and any actions required to lift it, as those updates will inform the program’s development timeline and potential impact on the company’s outlook.